Kayentis Raises Further €5M in Funding
Summary
The company intends to use the funds to scale-up its operations in North America to support clinical trials. Since 2003, Kayentis has been active in clinical development, with a specialization in eCOA solutions for phases II/III across a broad range of therapeutic areas. Over the years, it has developed a range of services and has enlarged its portfolio beyond eCOA solutions to support the new normal of decentralized and hybrid trials. Whilst Kayentis is currently focusing on expanding its US operations, where US-based sponsor study teams lead one-third of its projects, the company is also active across Europe and Asia. The company has conducted digital data collection for over 280 clinical trials in 85 countries (18,000 sites and 98,000 patients), employing 120 languages.
Funding
Review available funding amount, funding date, investors, and linked company information related to Kayentis Raises Further €5M in Funding in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
